Navidea Biopharmaceuticals to Present at the JMP Securities Healthcare Conference
CEO to Provide Business and Development Program Updates
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents, today announced that Dr. Mark Pykett, Navideas President and Chief Executive Officer, will participate at the JMP Securities Healthcare Conference on July 12-13, 2012 at the Peninsula Hotel in New York City. Dr. Pykett will provide an update of the Company and its development programs on Thursday, July 12, 2012 at 12:30 PM EDT.
Investors and the public are invited to listen to a live webcast of Dr. Pyketts presentation at http://wsw.com/webcast/jmp18/navb/. Following the conference, the webcast will be archived for approximately 30 days.
About Navidea Biopharmaceuticals, Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing three radiopharmaceutical agent platforms Lymphoseek®, AZD4694 and RIGScanTM to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and ultimately patient care. Navideas strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Companys pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals (NAVB)
Brent Larson, Sr. VP & CFO
Source: Navidea Biopharmaceuticals, Inc.Copyright Business Wire 2012